Aviado · Research
Longevity Daily
Monday, October 26, 2026
Listen
Today's Brief
Life Biosciences has just published initial human results from what may be the first cellular reprogramming trial ever run in people — a milestone the longevity field has been building toward for years. In cognitive health, University of Bonn researchers reset neural stem cells by 60 years epigenetically, and Pharmacy Times delivers a candid verdict on whether Neuriva actually earns its market share. A rapamycin skin cream cut biological skin age by two years in four weeks, while Aviado's new analysis maps exactly how panax ginseng suppresses the IL-6 inflammation driving silent aging. Novo Nordisk's semaglutide protein data rounds out a landmark issue.
10 stories2 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Scientists Converted Blood Cells Into Neural Stem Cells — and Reset Their Epigenetic Clock 60 Years
Researchers at the University of Bonn converted immature blood cells directly into neural stem cells, then measured their biological age using epigenetic clocks — and found the resulting cells registered approximately 60 years younger than the donor tissue. The experiment is still lab-based and far from a clinical intervention, but it demonstrates that the act of cell-type conversion itself can drive a dramatic epigenetic reset without full dedifferentiation. For those tracking the reprogramming space, this provides fresh mechanistic evidence that age reversal in brain-relevant cells is achievable — a meaningful step toward therapeutic applications.
Read more →Neuriva Is One of America's Best-Selling Brain Supplements. Pharmacists Say the Evidence Doesn't Match the Hype.
Pharmacy Times takes a rigorous look at Neuriva, whose two primary ingredients — Neurofactor (coffee fruit extract) and phosphatidylserine — have limited and inconsistent human trial data despite the brand's confident cognitive-decline messaging. The review finds that safety and effectiveness remain largely unsubstantiated for the claims being made to the rapidly growing 65+ demographic. If you're spending money on brain health supplements, this is essential reading before your next purchase.
Read more →Supplements & Compounds
A Rapamycin Skin Cream Rolled Back Biological Skin Age by Two Years — In Just Four Weeks
Early trial data covered by Wired show that participants using a topical mTOR-inhibiting rapamycin cream lowered the biological age of their skin by an average of two years after just four weeks — one of the first measurable epigenetic age-reversal results in humans using a pharmacological agent. The cream sidesteps the systemic exposure concerns that have complicated oral rapamycin discussions, making it a more accessible entry point for those curious about mTOR inhibition. A wave of biotech companies is now racing to replicate and expand these findings.
Read more →David Sinclair Predicts Peptides Will Do for Longevity What GLP-1 Did for Weight Loss — 3 Backed by Real Science
David Sinclair is publicly predicting that longevity-targeted peptides represent the next major pharmacological wave, drawing a direct parallel to how GLP-1 drugs transformed metabolic medicine. BoxLife Magazine identifies three peptides — BPC-157, Epitalon, and Humanin — with actual peer-reviewed data behind them, ranging from tissue repair to mitochondrial protection. Most evidence is still preclinical or early-stage, but understanding which claims have substance is worth doing now, before the market hype cycle takes over.
Read more →How Panax Ginseng Targets the IL-6 Inflammation Marker Quietly Driving Premature Aging
Chronic low-grade inflammation, measured by IL-6, drives fatigue, poor recovery, and long-term health decline — and most people with elevated levels feel fine and have no idea. Aviado's analysis of multiple large-scale studies shows that standardized Panax ginseng extract (1–3g daily, 5–20% ginsenosides) reliably lowers IL-6 across healthy adults, pre-diabetics, and those with metabolic issues, with measurable results appearing within 8–12 weeks. If you're looking for one supplement specifically targeting this inflammatory pathway, ginseng has some of the most consistent human evidence available — just verify the ginsenoside content on the label.
Read the full Aviado analysis →Research & Papers
Life Biosciences Publishes First Human Results From a Cellular Reprogramming Trial
Life Biosciences has released initial results from what appears to be the first-ever human clinical trial of partial cellular reprogramming — the long-anticipated technology that resets epigenetic age markers while leaving cell identity intact. Reprogramming with Yamanaka factors has consistently extended healthspan in aged mice; this trial marks the crucial first test of whether the same approach is safe and measurable in people. This edition of Fight Aging! also covers advances in CAR-NK cell therapy engineered in situ via mRNA, signaling a broadening front in rejuvenation biotechnology. If the human reprogramming data hold up to independent scrutiny, this could mark the most significant milestone in longevity medicine since rapamycin's lifespan effects were first documented.
Read more →Novo Nordisk Says Semaglutide Triggers the Same Protein Changes Seen in Biological Aging Reversal
New internal research from Novo Nordisk, the maker of Ozempic and Wegovy, suggests semaglutide does more than suppress appetite: by tracking changes to thousands of proteins in people using the drug, researchers found shifts closely resembling the protein signatures associated with slowed biological aging. The data positions GLP-1 drugs as potential anti-aging interventions, though the findings come from the manufacturer and await independent peer review. For the growing share of adults using semaglutide for weight or metabolic reasons, this adds a meaningful new dimension to the long-term health calculus.
Read more →Lifestyle & Nutrition
The World's Next Blue Zone May Be a Small Italian Village Where Women Are Reaching 100 at Remarkable Rates
Blue Zones founder Dan Buettner has identified a small Italian village where women are reaching age 100 at extraordinary rates, attributing the pattern to deep female friendships, shared community responsibilities, and unintentional daily movement built into the village's physical layout. The finding reinforces the Blue Zones framework — that longevity is less about individual optimization and more about the social and physical environment you're embedded in. It's a useful counterweight to the supplement-heavy framing of longevity: your social architecture may matter more than your stack.
Read more →A Longevity Doctor With Hundreds of Patients Says These 5 'Boring' Habits Are What Actually Work
In a field saturated with expensive interventions and biometric optimization, a clinician with a large patient population is pointing back to fundamentals: the habits that consistently correlate with slower biological aging are unglamorous, widely accessible, and mostly free. The piece is a useful reality check against the premium longevity industry's push toward complexity and cost. If you've been wondering whether your current routine needs an overhaul, this is a grounding read before adding anything new.
Read more →Industry & Policy
Bausch + Lomb Upgrades Its AREDS Eye Formula With B-Vitamins After Study Links Them to Reduced AMD Risk
Bausch + Lomb has launched PreserVision AREDS3, adding a B-vitamin complex to the existing AREDS2 formula after a cardiovascular study found a statistically significant association between specific B-vitamin supplementation and reduced age-related macular degeneration risk. The move updates the most widely used eye supplement formula in the US market. For anyone already taking AREDS2 for AMD prevention, this provides a concrete reason to ask your ophthalmologist about switching formulations.
Read more →